Physician profile
Daniel S Hurd
NPI 1841290897
$545,400.11
in general payments reported to CMS, 2019-2025
29 companies · $117K in 2025
The $117K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $23K · 2021: $21K · 2022: $35K · 2023: $115K · 2024: $144K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $321K · Travel and Lodging: $40K · Food and Beverage: $9,381 · Consulting Fee: $6,250 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $320,519.25 |
| Travel and Lodging | $40,208.46 |
| Food and Beverage | $9,381.38 |
| Consulting Fee | $6,250.00 |
| Education | $178.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $215,326.00 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Abbvie INC. | $121,775.81 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $61,742.55 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $60,521.31 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $23,938.45 | 2019-2025 | |
| Dermavant Sciences, INC. | $22,405.88 | 2023-2024 | Vtama |
| Genzyme Corporation | $20,767.31 | 2019-2025 | |
| Pfizer INC. | $16,944.70 | 2019-2024 | |
| Janssen Biotech, INC. | $340.16 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $245.22 | 2020-2024 | Winlevi |
| Incyte Corporation | $230.68 | 2022-2025 | Opzelura |
| Amgen INC. | $225.16 | 2020-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $198.15 | 2019-2020 | |
| Leo Pharma INC. | $159.38 | 2019-2025 | Adbry |
| Genentech USA, INC. | $128.65 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $110.55 | 2022-2025 | Nemluvio, Epsolay |
| Ucb, INC. | $44.90 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.74 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $36.04 | 2023-2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $34.76 | 2022-2023 | Nuzyra |
| Organon LLC | $34.61 | 2025 | Vtama |
| Almirall LLC | $23.87 | 2021 | |
| Celgene Corporation | $23.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.01 | 2022 | |
| Blueprint Medicines Corporation | $20.21 | 2023 | |
| Dusa Pharmaceuticals, INC. | $18.44 | 2019 | |
| Kyowa Kirin, INC. | $15.60 | 2022 | |
| Biofrontera INC. | $13.77 | 2022 | |
| Hill Dermaceuticals, INC. | $9.68 | 2024 | Tolak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hurd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.